Type: Keynote Therapeutic: Cardiovascular Medicine,Diabetes, & Metabolism,Endocrinology,Screening & Prevention
Friday May 11 8:30am to 9:30am Location: Lecture Hall 1 Credits: 1 Mainpro+
This presentation aims to provide a cutting edge and contemporary discussion about the role of LDL-C in the pathophysiology of atherosclerosis and associated complications. Recent data from large randomized trials will be presented, and the clinical implications of these data in patients at risk of cardiovascular disease will be emphasized. Guideline updates will also be discussed and practical guidance on achieving LDL-C targets provided.
To discuss the evidence of LDL-C in the context of primary and secondary prevention of atherosclerotic cardiovascular disease.
To evaluate the recent clinical trial evidence with lipid lowering approaches in secondary prevention.
To discuss the current clinical practice guidelines in dyslipidemia and provide practical advice.
Subodh Verma MD, PhD, FRCSC, FAHA Dr Subodh Verma is a cardiac surgeon‐scientist at St Michael’s Hospital and Professor at the University of Toronto. He has received the Howard Morgan Award for Distinguished Achievements in Cardiovascular Research, and the Royal College of Physicians and Surgeons of Canada Gold Medal in Surgery. He is a member of the American Association of Thoracic Surgeons (AATS) and the College of New Scholars, Artists and Scientists, Royal Society of Canada. Dr Verma has an h‐index of 61, with 15,029 total citations to 289 publications.
Dr Verma's has co‐authored two state‐of‐the‐art NEJM reviews on mitral valve repair and bicuspid aortopathy. His meta‐analysis revealing that coronary artery bypass surgery is superior to angioplasty in patients with diabetes has been used by the American College of Cardiology and the Canadian Cardiovascular Society (CCS) to shape the recommendations for best revascularization choice in individuals with diabetes. He is a past/present contributor to several CCS guidelines as well as the next updates of the Canadian Diabetes Association guidelines and the AATS Consensus Guidelines on bicuspid aortic valve related
aortopathy. Dr Verma has served on the American Heart Association Council on Cardiovascular Surgery and Anesthesia since 2008. Dr Verma is heavily invested in clinical trial work with a major focus on diabetes, dyslipidemia and heart failure. He sits on the steering committees of the global EMPEROR‐Reduced and EMPEROR‐Preserve trials and is a national lead investigator of the Dapa‐HF trial. He spearheads the CARDIOLINK clinical trials platform at St. Michael's Hospital which is conducting studies on surgical strategies for cerebral protection during aortic surgery (ACE) and mitral valve repair (CAMRA), the impact of PCSK9 inhibition on vulnerable plaques (CEA) and saphenous vein graft patency following coronary artery bypass surgery (NEWTON CABG) and post‐cardiac surgery atrial fibrillation (SEARCH‐AF). Trials on anticoagulation therapy for bioprosthetic heart valves and anti‐inflammatory management of critical limb ischemia are in the pipeline. Dr Verma also oversees a pre‐clinical research team that focuses on identifying novel biomarkers in cardiovascular health and developing innovative cardiovascular remedies. This research program has yielded 2 United States patents and is supported by the Canadian Foundation for Innovation, Canadian Institutes of Health Research and Heart & Stroke Foundation of Canada.